AzurRx BioPharma Inc (AZRX) Initiated with a Buy at Maxim Group


In a report released today, Caroline Palomeque from Maxim Group initiated coverage with a Buy rating on AzurRx BioPharma Inc (AZRX) and a price target of $5. The company’s shares closed yesterday at $1.72.

Palomeque commented:

“We are initiating coverage of Buy rating and a $5 price target. The company’s lead candidate is MS1819-SD, an oral, non-animal derived, recombinant lipase enzyme for the treatment of exocrine pancreatic insufficiency (EPI) in cystic fibrosis (CF) and chronic pancreatitis (CP).”

According to TipRanks.com, Palomeque has currently no stars on a ranking scale of 0-5 stars, with an average return of -12.3% and a 33.3% success rate. Palomeque covers the Healthcare sector, focusing on stocks such as Soleno Therapeutics Inc, VistaGen Therapeutics, and Anavex Life Sciences.

AzurRx BioPharma Inc has an analyst consensus of Strong Buy, with a price target consensus of $6.33.

See today’s analyst top recommended stocks >>

Based on AzurRx BioPharma Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $2.57 million. In comparison, last year the company had a GAAP net loss of $2.48 million.

Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AZRX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

AzurRx BioPharma, Inc. is a development stage company, which engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. It offers MS1819 and AZX1101 that are therapeutic proteins products under development. The company was founded on January 30, 2014 and is headquartered in Brooklyn, NY.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts